Media stories about Johnson & Johnson (NYSE:JNJ) have trended extremely negative this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Johnson & Johnson earned a daily sentiment score of -5.00 on their scale. InfoTrie also gave news articles about the company an news buzz score of 0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news articles that may have effected Johnson & Johnson’s analysis:
- Johnson & Johnson to Participate in Barclays Global Healthcare Conference (finance.yahoo.com)
- Apple and Johnson & Johnson team up on heart study (fortune.com)
- Where Will Johnson & Johnson Be in 1 Year? (fool.com)
- Johnson & Johnson and Apple to Study If Apple Watches Can Reduce Stroke Risk in Seniors (fool.com)
- Why Apple and Johnson & Johnson’s new heart study is a big deal for digital health (cnbc.com)
A number of equities analysts recently weighed in on JNJ shares. Cantor Fitzgerald reissued a “buy” rating and set a $168.00 price target on shares of Johnson & Johnson in a research note on Thursday, January 23rd. Wells Fargo & Co boosted their target price on Johnson & Johnson from $155.00 to $165.00 and gave the company an “overweight” rating in a research report on Thursday, January 9th. Raymond James upped their price target on shares of Johnson & Johnson from $147.00 to $161.00 and gave the stock an “outperform” rating in a report on Thursday, January 23rd. Morgan Stanley upgraded Johnson & Johnson from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $145.00 to $170.00 in a report on Tuesday, December 17th. Finally, Barclays upgraded Johnson & Johnson from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $140.00 to $173.00 in a report on Thursday, December 19th. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Johnson & Johnson presently has a consensus rating of “Buy” and a consensus target price of $163.27.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $1.88 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.01. Johnson & Johnson had a net margin of 22.18% and a return on equity of 39.27%. The business had revenue of $20.75 billion during the quarter, compared to the consensus estimate of $20.83 billion. During the same period in the previous year, the firm posted $1.97 earnings per share. The business’s revenue for the quarter was up 1.7% compared to the same quarter last year. Analysts expect that Johnson & Johnson will post 9.03 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 25th will be issued a $0.95 dividend. The ex-dividend date of this dividend is Monday, February 24th. This represents a $3.80 annualized dividend and a yield of 2.64%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 43.78%.
In other Johnson & Johnson news, COO Michael E. Sneed sold 58,128 shares of the stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $149.39, for a total transaction of $8,683,741.92. Following the sale, the chief operating officer now directly owns 107,511 shares of the company’s stock, valued at approximately $16,061,068.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Hubert Joly purchased 5,000 shares of the business’s stock in a transaction on Friday, December 13th. The shares were bought at an average cost of $141.28 per share, for a total transaction of $706,400.00. Following the completion of the transaction, the director now directly owns 5,000 shares in the company, valued at approximately $706,400. The disclosure for this purchase can be found here. Company insiders own 0.23% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Further Reading: What are gap-down stocks?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.